Researchers plan to combine Redcivir with anti-inflammatory drugs in hopes of achieving a “two-in-one” effect

It’s hard to be optimistic about the treatment of the new coronavirus as it remains so elusive, but scientists and researchers are making progress every day,media BGR reported. The antiviral drug redsievir, for example, has shown potential and is currently being used in the treatment of COVID-19 patients. The efficacy of Ridsievir may be limited, but the researchers believe it could be a powerful tool if combined with another drug.

“I think Ridsiewe will be an important tool, but we need to find other ways to help our patients,” lead researcher Dr. Aneesh Mehta of the NIH Redsiewe trial at Emory University told CBS News.

In the next phase of the trial, Mehta said, he and his colleagues will combine ridsion with an anti-inflammatory drug that can prevent organ damage by appeasing the inflamed immune system. “What Redsiewe did was stop the sparks — and the immunomodulator would hopefully put dirt on the fire and put it out,” Mehta explained to CBS News. This “two-for-one” treatment could have a significant impact on the rehabilitation of COVID-19 patients.

The researchers hope that combining Redcivir with anti-inflammatory drugs will improve recovery rates and reduce mortality in ways that Redcivir can’t do with a single drug. It took researchers years to determine the need for a combination of drugs to treat AIDS, and now the lesson is being applied to COVID-19.

But there are some notes worth noting, for example, that Ridsiewe is not entirely ready-made. Last week, drugmaker Gilead announced it would donate 1.5million bottles of antiviral drugs to countries around the world over the next six weeks. Of those bottles, 607,000 will be sent to U.S. hospitals, which the U.S. Department of Health and Human Services says will be enough to treat about 78,000 patients.